News | February 07, 2026
Novo Nordisk threatens legal action over Hims & Hers ‘knockoff’ semaglutide pill
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Company to launch product after the expiry of semaglutide patent in India
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Experts caution that realizing AI’s potential requires careful management and risk mitigation
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Subscribe To Our Newsletter & Stay Updated
